The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients

European Journal of Cancer

Volumn 45, Issue 17, 2009, Pages 3064-3073

  Orgéas, Chantal C ^a   Hall, Per ^a   Wedrén, Sara ^a   Dickman, Paul W ^a   Czene, Kamila ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Endometrial cancer; Menopause hormone therapy; Mortality; Myometrial invasion; Postmenopausal; Relative survival; Tumour grade

Indexed keywords

CONJUGATED ESTROGEN; DIENESTROL; ESTRADIOL; ESTRIOL; ESTROGEN; GESTAGEN; HYDROXYPROGESTERONE; NANDROLONE PHENPROPIONATE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MYOMETRIUM; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; SWEDEN; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGE FACTORS; AGED; ENDOMETRIAL NEOPLASMS; EPIDEMIOLOGIC METHODS; ESTRADIOL CONGENERS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; POSTMENOPAUSE; PROGESTERONE CONGENERS; PROGNOSIS; SWEDEN;

EID: 70350580945     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.012     Document Type: Article

References (41)

1. Cushing K.L., Weiss N.S., Voigt L.F., McKnight B., and Beresford S.A. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol 91 (1998) 35-39
2. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., and Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85 (1995) 304-313
3. Lacey Jr. J.V., Brinton L.A., Lubin J.H., Sherman M.E., Schatzkin A., and Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 14 (2005) 1724-1731
4. Persson I., Weiderpass E., Bergkvist L., Bergstrom R., and Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Cause Control 10 (1999) 253-260
5. Weiderpass E., Baron J.A., Adami H.O., et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 353 (1999) 1824-1828
6. Beral V., Bull D., and Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
7. Beresford S.A., Weiss N.S., Voigt L.F., and McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349 (1997) 458-461
8. Pike M.C., Peters R.K., Cozen W., et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89 (1997) 1110-1116
9. Weiderpass E., Adami H.O., Baron J.A., et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91 (1999) 1131-1137
10. Lacey Jr. J.V., Leitzmann M.F., Chang S.C., et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer 109 (2007) 1303-1311
11. Sturdee D.W., Ulrich L.G., Barlow D.H., et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG 107 (2000) 1392-1400
12. Anderson G.L., Judd H.L., Kaunitz A.M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (2003) 1739-1748
13. Chapman J.A., DiSaia P.J., Osann K., Roth P.D., Gillotte D.L., and Berman M.L. Estrogen replacement in surgical stages I and II endometrial cancer survivors. Am J Obstet Gynecol 175 (1996) 1195-1200
14. Collins J., Donner A., Allen L.H., and Adams O. Oestrogen use and survival in endometrial cancer. Lancet 2 (1980) 961-964
15. Khan M., Mori M., Sakauchi F., et al. Risk of endometrial cancer mortality by ever-use of sex hormones and other factors in Japan. Asian Pac J Cancer Prev 7 (2006) 260-266
16. Mittal K.R., and Barwick K.W. Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis. Gynecol Oncol 49 (1993) 197-201
17. Nyholm H.C., Nielsen A.L., and Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics. Gynecol Oncol 49 (1993) 229-235
18. Robboy S.J., and Bradley R. Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 54 (1979) 269-277
19. Schairer C., Adami H.O., Hoover R., and Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 8 (1997) 59-65
20. Shapiro J.A., Weiss N.S., Beresford S.A., and Voigt L.F. Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology 9 (1998) 99-101
21. Smith D.C., Prentice R.L., and Bauermeister D.E. Endometrial carcinoma: histopathology, survival, and exogenous estrogens. Gynecol Obstet Invest 12 (1981) 169-179
22. Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Lindgren A., and Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Cause Control 10 (1999) 277-284
23. Moradi T., Weiderpass E., Signorello L.B., Persson I., Nyren O., and Adami H.O. Physical activity and postmenopausal endometrial cancer risk (Sweden). Cancer Causes Control 11 (2000) 829-837
24. Weiderpass E., Adami H.O., Baron J.A., et al. Organochlorines and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 9 (2000) 487-493
25. Weiderpass E., Persson I., Adami H.O., Magnusson C., Lindgren A., and Baron J.A. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Cause Control 11 (2000) 185-192
26. Weiderpass E., Persson I., Melhus H., Wedren S., Kindmark A., and Baron J.A. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 21 (2000) 623-627
27. Begg C., and Gray R. Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika 71 (1984) 11-18
28. Ederer F., Axtell L.M., and Cutler S.J. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6 (1961) 101-121
29. Persson I., Yuen J., Bergkvist L., and Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 67 (1996) 327-332
30. Suriano K.A., McHale M., McLaren C.E., Li K.T., Re A., and DiSaia P.J. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 97 (2001) 555-560
31. Berrino F., De Angelis R., Sant M., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 8 (2007) 773-783
32. Mackenbach J.P., Stirbu I., Roskam A.J., et al. Socioeconomic inequalities in health in 22 European countries. N Engl J Med 358 (2008) 2468-2481
33. Verdecchia A., Baili P., Quaglia A., et al. Patient survival for all cancers combined as indicator of cancer control in Europe. Eur J Public Health 18 (2008) 527-532
34. Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., and Coebergh J.W. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44 (2008) 1345-1389
35. Collins J.A., Blake J.M., and Crosignani P.G. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11 (2005) 545-560
36. Daling J.R., Malone K.E., Doody D.R., et al. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev 12 (2003) 1175-1181
37. Gapstur S.M., Morrow M., and Sellers T.A. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 281 (1999) 2091-2097
38. Rosenberg L.U., Granath F., Dickman P.W., et al. Menopausal hormone therapy in relation to breast cancer characteristics, prognosis: a cohort study. Breast Cancer Res 10 (2008) R78
39. Mascarenhas C., Lambe M., Bellocco R., et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119 (2006) 2907-2915
40. Beral V., Bull D., Green J., and Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369 (2007) 1703-1710
41. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333